SAFETY

作品数：1776被引量：2613H指数：19
导出分析报告
相关领域：医药卫生更多>>
相关作者：黎忠文王春喜李乐民李仲学熊光泽更多>>
相关机构：清华大学机械工业仪器仪表综合技术经济研究所电子科技大学北京大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划中国博士后科学基金国家高技术研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Chinese Medical Journalx
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Population pharmacokinetics of Ainuovirine and exposure–response analysis in human immunodeficiency virus-infected individuals
《Chinese Medical Journal》2024年第20期2473-2482,共10页Xiaoxu Han Jin Sun Yihang Zhang Taiyi Jiang Qingshan Zheng Haiyan Peng Yao Wang Wei Xia Tong Zhang Lijun Sun Xinming Yun Hong Qin Hao Wu Bin Su 
supported by the National“Thirteenth Five-year Period”Major Innovative Drug Research and Development Key Project of the Ministry of Science and Technology of the PR.China(No.2017ZX09201007);the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission(Nos.2022-1-007 and 2022-2-018);the“Climbing the peak(Dengfeng)”Talent Training Program of Beijing Hospitals Authority(No.DFL20191701);Beijing Health Technologies Promotion Program(No.BHTPP202002);the Beijing Key Laboratory for HIV/AIDS Research(No.BZ0089).
Background:Ainuovirine(ANV)is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus(HIV)type 1 infection.This study aimed to evaluate the population pharm...
关键词：Human immunodeficiency virus Ainuovirine Population pharmacokinetics Expose-response model SAFETY Acquired immune deficiency syndrome Antiretroviral therapy 
The meta-analyses on effectiveness and safety of colorectal cancer screening
《Chinese Medical Journal》2024年第12期1471-1473,共3页Pei Li Xueyang Zeng Zuoxiang Liu Jichun Yang Yueying Li Le Gao Hongmei Zeng Lin Zhang Feng Sun 
supported by a grant from the National Natural Science Foundation of China(No.72074011)
To the Editor:The colorectal cancer(CRC)is the fourthmost common cause of cancer deaths in China that was treated as a public health threat,accounting for approximately 10%of all the cancer-caused mortalities each yea...
关键词：COLORECTAL PREVENTION CANCER 
Safety of high-carbohydrate fluid diet 2 h versus overnight fasting before non-emergency endoscopic retrograde cholangiopancreatography:A single-blind,multicenter,randomized controlled trial
《Chinese Medical Journal》2024年第12期1437-1446,共10页Wenbo Meng Joseph W.Leung Zhenyu Wang Qiyong Li Leida Zhang Kai Zhang Xuefeng Wang Meng Wang Qi Wang Yingmei Shao Jijun Zhang Ping Yue Lei Zhang Kexiang Zhu Xiaoliang Zhu Hui Zhang Senlin Hou Kailin Cai Hao Sun Ping Xue Wei Liu Haiping Wang Li Zhang Songming Ding Zhiqing Yang Ming Zhang Hao Weng QingyuanWu Bendong Chen Tiemin Jiang Yingkai Wang Lichao Zhang Ke Wu Xue Yang Zilong Wen Chun Liu LongMiao Zhengfeng Wang Jiajia Li Xiaowen Yan Fangzhao Wang Lingen Zhang Mingzhen Bai Ningning Mi XianzhuoZhang Wence Zhou Jinqiu Yuan Azumi Suzuki Kiyohito Tanaka Jiankang Liu Ula Nur Elisabete Weiderpass Xun Li 
Background:Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography(ERCP),the benefits and safety of high-carbohydrate fluid diet(CFD)intake 2 h before ERCP remain unclear.This...
关键词：Endoscopic retrograde cholangiopancreatography ERCP CARBOHYDRATE FASTING SAFETY COMPLICATIONS Enhanced recovery after surgery Randomized controlled trial 
Reasons,safety and efficacy analysis for conversion of HAART to TAF/ FTC/BIC among HIV-infected patients被引量：1
《Chinese Medical Journal》2023年第24期2931-2937,共7页Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao 
supported by the Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20191802);Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(No.ZYLX202126);Capital’s Funds for Health Improvement and Research(No.2020-2-2174)
Background:This study aimed to determine the reasons for conversion and elucidate the safety and efficacy of transition to tenofovir alafenamide/emtricitabine/bictegravir sodium(TAF/FTC/BIC)in highly active antiretrov...
关键词：HIV Antiretroviral therapy highly active CONVERSION Viral load Efficacy SAFETY 
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk:a single-center study
《Chinese Medical Journal》2023年第11期1358-1360,共3页Meng Chai Haitao Zhang Lixia Yang Jing Liang Hongya Han Xiaoli Liu Xiaoteng Ma Yan Liu Dongmei Shi Yingxin Zhao Yuyang Liu Yujie Zhou 
National Key Research and Development Program of China(No.2017YFC0908800);Beijing Municipal Administration of Hospitals’Mission plan(No.SML20180601)
Low-density lipoprotein cholesterol(LDL-C)is an independent risk factor for atherosclerotic cardiovascular disease(ASCVD).Even after lipid-lowering therapy(LLT)with statins or statin–ezetimibe,a large proportion of p...
关键词：PATIENTS LIPID CARDIOVASCULAR 
Aggressive versus controlled fluid resuscitation in acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials被引量：1
《Chinese Medical Journal》2023年第10期1166-1173,共8页Kun He Lin Gao Zihan Yang Yuelun Zhang Tianrui Hua Wenmo Hu Dong Wu Lu Ke 
National Natural Science Foundation of China(Nos.32170788,82070665,82200722);National High Level Hospital Clinical Research Funding(No.2022-PUMCH-B-023);National key clinical specialty construction project(No.ZK108000)
Background:Early fluid resuscitation is one of the fundamental treatments for acute pancreatitis(AP),but there is no consensus on the optimal fluid rate.This systematic review and meta-analysis aimed to compare the ef...
关键词：Acute pancreatitis Aggressive fluid resuscitation Controlled fluid resuscitation EFFICACY SAFETY Systemic review 
Diagnostic accuracy and safety of Dermatophagoides pteronyssinus extracts used for skin prick test
《Chinese Medical Journal》2022年第21期2563-2569,共7页Rui Tang Xiaohong Lyu Yuxi Liu Ruiqi Wang Lianglu Wang Hong Li Jinlyu Sun Yuxiang Zhi Jianqing Gu Kai Guan Liping Wen Zixi Wang Lisha Li Le Cui Yingyang Xu Junxiong Zhou Tao Xu Jia Yin 
National Science and Technology Major Projects(No. 2014ZX09102041-008);Beijing Science and technology plan(No. Z131100006813047);CAMS Innovation Fund for Medical Sciences(No. 2016-I2M-1-003)
Background:Dermatophagoides pteronyssinus is a common allergen causing allergic diseases in China.The aim of this study was to evaluate the efficacy and safety of D.pteronyssinus extracts produced by Peking Union Medi...
关键词：Dermatophagoides pteronyssinus Allergen extract allergy Skin prick test Immunoglobulin E ALLERGY 
Coronavirus disease 2019 vaccines:landscape of global studies and potential risks被引量：1
《Chinese Medical Journal》2021年第17期2037-2044,共8页Hu-Da-Chuan Jiang Yan-Yang Tao Si-Yue Jia Jing-Xin Li Feng-Cai Zhu 
With the outbreak of the coronavirus disease 2019(COVID-19)pandemic,the importance of vaccines in epidemic prevention and public health has become even more obvious than ever.However,the emergence of multiple severe a...
关键词：Severe acute respiratory syndrome coronavirus 2 COVID-19 VACCINE IMMUNOGENICITY SAFETY Clinical trial 
Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019:a systematic review and network meta-analysis combining 66 trials被引量：1
《Chinese Medical Journal》2021年第16期1920-1929,共10页Shan-Shan Wu Qing-Xin Zhou Xue-Yang Zeng Jing-Xue Zhang Zhi-Rong Yang Qing-Qing Yang Zi-Lu Zhang Ya-Hong Chen Feng Sun Si-Yan Zhan 
the National Natural Science Foundation of China(No.72074011);the Special Project for Major Infectious Disease of Peking University Health Program of China(No.BMU2020HKYZX010);the National Key Technology R&D Program of China(No.2020YFC0840800).
Background:The global pandemic coronavirus disease 2019(COVID-19)has become a major public health problem and presents an unprecedented challenge.However,no specific drugs were currently proven.This study aimed to eva...
关键词：SARS-CoV-2 COVID-19 Pharmacological intervention Network meta-analysis EFFECTIVENESS SAFETY 
Immunogenicity and safety of a recombinant fusion protein vaccine(V-01)against coronavirus disease 2019 in healthy adults:a randomized,double-blind,placebo-controlled,phaseⅡtrial被引量：1
《Chinese Medical Journal》2021年第16期1967-1976,共10页Ya-Jun Shu Jian-Feng He Rong-Juan Pei Peng He Zhu-Hang Huang Shao-Min Chen Zhi-Qiang Ou Jing-Long Deng Pei-Yu Zeng Jian Zhou Yuan-Qin Min Fei Deng Hua Peng Zheng Zhang Bo Wang Zhong-Hui Xu Wu-Xiang Guan Zhong-Yu Hu Ji-Kai Zhang 
the Emergency Key Program of Guangzhou Laboratory(No.EKPG21-21)。
Background:Innovative coronavirus disease 2019(COVID-19)vaccines,with elevated global manufacturing capacity,enhanced safety and efficacy,simplified dosing regimens,and distribution that is less cold chain-dependent,a...
关键词：COVID-19 PhaseⅡ Clinical trial Recombinant fusion protein vaccine SAFETY IMMUNOGENICITY 
全选清除导出
共6页<123456>
检索报告 对象比较 聚类工具 使用帮助 返回顶部